Japan filing for Nexavar in thyroid cancer
This article was originally published in Scrip
Executive Summary
Bayer has submitted a regulatory filing in Japan seeking the approval of Nexavar (sorafenib) for the additional indication of locally advanced or metastatic thyroid cancer.